BAYER AG
🇩🇪Germany
- Country
- 🇩🇪Germany
- Ownership
- Public
- Established
- 1863-08-01
- Employees
- 99.7K
- Market Cap
- $30.1B
- Website
- http://www.bayer.com
A Study to Learn About the Taste of Vericiguat Given in Liquid Form in Healthy Male Participants Aged 18 to 45 Years
Phase 1
Completed
- Conditions
- Heart Failure
- Interventions
- Drug: Formulation 1Drug: Formulation 2Drug: Formulation 3Drug: Formulation 4Drug: Formulation 5 (placebo)
- First Posted Date
- 2024-06-25
- Last Posted Date
- 2024-10-07
- Lead Sponsor
- Bayer
- Target Recruit Count
- 19
- Registration Number
- NCT06474208
- Locations
- 🇩🇪
Clinical Research Services | Clinical Research Services Mannheim - Phase one unit, Mannheim, Baden-Württemberg, Germany
A Study to Learn More About How Well BAY 2927088 Works and How Safe it is Compared With Standard Treatment, in Participants Who Have Advanced Non-small Cell Lung Cancer (NSCLC) With Mutations in the Genes of Human Epidermal Growth Factor Receptor 2 (HER2)
Phase 3
Recruiting
- Conditions
- Advanced Non-small Cell Lung CancerHER2 Mutation
- Interventions
- First Posted Date
- 2024-06-11
- Last Posted Date
- 2025-04-08
- Lead Sponsor
- Bayer
- Target Recruit Count
- 278
- Registration Number
- NCT06452277
- Locations
- 🇺🇸
Memorial Cancer Institute at Miramar, Miramar, Florida, United States
🇺🇸Allegheny General Hospital, Pittsburgh, Pennsylvania, United States
🇧🇬MHAT Sveta Marina EAD, Varna, Bulgaria
A Study to Learn About the Safety of BAY3283142 in People With Mild to Moderate High Blood Pressure
Phase 1
Recruiting
- Conditions
- Chronic Kidney DiseaseArterial Hypertension
- Interventions
- Drug: Placebo to BAY3283142
- First Posted Date
- 2024-05-24
- Last Posted Date
- 2025-04-15
- Lead Sponsor
- Bayer
- Target Recruit Count
- 72
- Registration Number
- NCT06428825
- Locations
- 🇩🇪
Clinical Research Services | Clinical Research Services Mannheim - Phase one unit, Mannheim, Baden-Württemberg, Germany
🇩🇪CRS Clinical Research Services Berlin GmbH, Berlin, Germany
A Study to Learn More About How Well 8 Milligram Aflibercept Works and How Safe it is in Chinese Participants With Diabetic Macular Edema
Phase 3
Active, not recruiting
- Conditions
- Diabetic Macular Edema
- Interventions
- Drug: 2 mg aflibercept (EYLEA, BAY 86-5321)Drug: 8 mg aflibercept (BAY 86-5321) (High Dose)Other: Sham
- First Posted Date
- 2024-05-21
- Last Posted Date
- 2025-04-30
- Lead Sponsor
- Bayer
- Target Recruit Count
- 333
- Registration Number
- NCT06422507
- Locations
- 🇨🇳
Aier Eye Hospital (LIAONING), Shenyang, Liaoning, China
🇨🇳The Second Hospital of Anhui medical university, Hefei, Anhui, China
🇨🇳Shanghai eye disease prevention and control center, Shanghai, China
A Study to Learn About Whether BAY H006689 Causes an Allergic Reaction When Applied as a Topical Gel in Healthy Participants
Phase 1
Completed
- Conditions
- PainHealthy Volunteers
- Interventions
- First Posted Date
- 2024-05-16
- Last Posted Date
- 2024-08-14
- Lead Sponsor
- Bayer
- Target Recruit Count
- 236
- Registration Number
- NCT06415019
- Locations
- 🇺🇸
TKL Research, Inc., Fair Lawn, New Jersey, United States
A Study to Learn About How Much Emodepside Gets Absorbed in the Blood and How Food Affects Its Absorption When Given as a New Type of Tablet to Healthy Participants
Phase 1
Completed
- Conditions
- Soil-transmitted Helminth InfectionOnchocerciasis (River Blindness)
- Interventions
- First Posted Date
- 2024-05-14
- Last Posted Date
- 2024-09-27
- Lead Sponsor
- Bayer
- Target Recruit Count
- 40
- Registration Number
- NCT06412926
- Locations
- 🇩🇪
NUVISAN GmbH Neu-Ulm, Neu-Ulm, Bayern, Germany
A Study to Learn About How BAY 3283142 Moves Into, Through, and Out of the Body After a Single Dose in Participants With Reduced Liver Function Compared to Participants With Normal Liver Function
- First Posted Date
- 2024-05-07
- Last Posted Date
- 2025-03-12
- Lead Sponsor
- Bayer
- Target Recruit Count
- 24
- Registration Number
- NCT06402721
- Locations
- 🇺🇸
Orlando Clinical Research Center (OCRC), Orlando, Florida, United States
A Study to Learn About How Food and Esomeprazole Affect the Level of BAY2927088 in the Blood When Taken Together in Healthy Participants
Phase 1
Completed
- Conditions
- EGFR MutationHER2 MutationHealthy VolunteersAdvanced Non-small Cell Lung Cancer
- Interventions
- First Posted Date
- 2024-04-22
- Last Posted Date
- 2024-07-05
- Lead Sponsor
- Bayer
- Target Recruit Count
- 21
- Registration Number
- NCT06378658
- Locations
- 🇺🇸
Parexel Baltimore - Early Phase Clinical Unit, Baltimore, Maryland, United States
An Observational Study to Learn About the Occurrence of Disseminated Intravascular Coagulation Among Adults With Sepsis in Japan
Active, not recruiting
- Conditions
- SepsisDisseminated Intravascular Coagulation
- Interventions
- Other: No study intervention
- First Posted Date
- 2024-04-18
- Last Posted Date
- 2025-05-06
- Lead Sponsor
- Bayer
- Target Recruit Count
- 5740
- Registration Number
- NCT06373159
- Locations
- 🇯🇵
Bayer, Tokyo, Japan
An Observational Study to Learn More About Vericiguat Treatment Patterns and Its Safety in People With Chronic Heart Failure With Reduced Ejection Fraction in Routine Medical Care in the United States
Completed
- Conditions
- Chronic Heart Failure With Reduced Ejection Fraction
- Interventions
- First Posted Date
- 2024-04-12
- Last Posted Date
- 2024-07-03
- Lead Sponsor
- Bayer
- Target Recruit Count
- 1400
- Registration Number
- NCT06363110
- Locations
- 🇺🇸
Bayer, Whippany, New Jersey, United States
© Copyright 2025. All Rights Reserved by MedPath